SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalBICO & VITK


Previous 10 Next 10 
To: David Dickter who wrote ()2/17/2000 1:47:00 PM
From: david sandel
   of 2395
 
Thursday February 17, 12:44 pm Eastern Time

Company Press Release

SOURCE: Biocontrol Technology, Inc.

Biocontrol Technology, Inc. Subsidiary,
IDT, Receives FDA Approval to
Continue Lung Cancer Study at the University of Texas
Medical Branch at Galveston

PITTSBURGH, Feb. 17 /PRNewswire/ -- Biocontrol Technology, Inc. (OTC Bulletin Board:
BICO - news) announced today that its subsidiary, IDT, Inc., in conjunction with HemoCleanse, Inc.
located in Lafayette, Indiana, has received FDA approval and Institutional Review Approval from
the University of Texas Medical Branch at Galveston to continue a human clinical trial to treat
patients with non-small cell lung cancer (NSCLC).

The clinical trial will utilize the ThermoChem technology and disposables to deliver
Perfusion-Induced Systemic Hyperthermia (PISH), a therapy in which core body temperature is
raised to 42 degrees C (107.6 degrees F) for two hours by direct extracorporeal (outside of the
body) heating of the blood. Non-small cell lung cancer is a combination of at least three malignant
cell structures found in the tissues of the lungs. Lung cancer remains a major cause of cancer
morbidity and mortality in the United States.

IDT completed the first phase of the FDA approved study, which involved five patients in July 1998.
That phase of the study involved patients with Stage IV non-small cell lung cancer where cancer had
spread to other parts of the body. Results of that study are pending publication.

In this most recent approval, the FDA allowed Stage IIIb patients to be included. Stage IIIb is
usually non-operative cancer that has spread to the chest wall or diaphragm near the lung or cancer
that has spread to the lymph nodes in the area that separates the two lungs or to the lymph nodes on
the other side of the chest or in the neck.

The objective of the clinical trial is to evaluate the ThermoChem technology as a delivery system for
Perfusion-Induced Systemic Hyperthermia in the treatment of non-small cell lung cancer with regard
to patient selection, tumor response, patient performance status, and patient survival.

In Perfusion-Induced Systemic Hyperthermia, the ThermoChem technology is composed of the
ThermoChem-HT System(TM) and ThermoChem-SB System(TM). The ThermoChem-HT System
heats and circulates the blood while maintaining core body temperature, and ThermoChem-SB
System balances blood chemistries on a ``real-time' basis and removes toxins from the blood. The
Company believes this interface between two systems is essential to safely deliver Perfusion-Induced
Systemic Hyperthermia.

IDT has been developing the ThermoChem technology as a safe delivery system for whole body and
regional hyperthermia since 1992. The FDA recently cleared the ThermoChem-HT System for
marketing where the intended use is to raise the core temperature of the peritoneum to 42 degrees C
(107.6 degrees F) by continuously lavaging (bathing) the peritoneum with sterile solution.
Intraperitoneal hyperthermia is part of an operative procedure used to treat patients with advanced
ovarian and gastrointestinal cancer.

Biocontrol Technology has its corporate offices in Pittsburgh, PA, and is involved in the development
and manufacture of biomedical devices and environmental products. IDT, Inc., a subsidiary of
Biocontrol also located in Pittsburgh, PA, holds exclusive worldwide marketing rights to the
ThermoChem-HT technology and related disposables for regional hyperthermia and the
ThermoChem technology and related disposables for whole body hyperthermia.

This press release contains statements of a forward-looking nature. Shareholders and potential
investors are cautioned that such statements are predictions and actual events or results may vary
significantly.

WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204

SOURCE: Biocontrol Technology, Inc.

More Quotes and News:
Biocontrol Technology Inc (OTC BB:BICO.OB - news)
Related News Categories: biotech, medical/pharmaceutical

Help

Copyright ¸ 2000 Yahoo! All Rights Reserved. Privacy Policy - Terms of Service
Copyright 2000 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is
expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any
errors or delays in the content, or for any actions taken in reliance thereon.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: david sandel who wrote (2382)2/24/2000 9:43:00 AM
From: Joe Lyddon
   of 2395
 
BICO action... why? . . WHY?!

I like it... but I don't like NOT knowing WHY!

Thank you,
Joe

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Joe Lyddon who wrote (2383)2/24/2000 1:16:00 PM
From: dogfish
   of 2395
 
company supposedly has a diabetes scanning device which does not require a finger prick. sounds like nothing, but talk to a diabetic and you'll see its a big deal. also, millions of shares are being bought and held by pros. its so cheap why not hold it? you might make a few thousand over time daytrading but you could make 100K holding

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dogfish who wrote (2384)2/24/2000 2:19:00 PM
From: Joe Lyddon
   of 2395
 
They have had that for years... That's why I bought it...
It has never been very stable & hard to sell & hard to get FDA approval... That's why it went south & stayed there for years... I didn't sell because it would've cost me $ in comm's. ...it's just been sleeping...Now, it's back to LIFE & can't find out WHY...

I will continue to hold it... why not...?

Thank you for trying...
Joe

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Joe Lyddon who wrote (2385)2/25/2000 12:32:00 AM
From: Ronald P. Margraf Sr.
   of 2395
 
Hi Joe,

Picked this up today. Like the story and hope to make some good monies on this. Looking for this to go to 1-1 1/2 in the next 5-7 days. The fundamentals look good and the T/As on this are looking like they could be dynamite.

Keep the faith. I think your wait will be well rewarded.;-))))

Catcha on the upside,

Ron

Share RecommendKeepReplyMark as Last Read


To: Joe Lyddon who wrote (2383)2/25/2000 12:35:00 AM
From: Ronald P. Margraf Sr.
   of 2395
 
Joe,

Look at it this way. It's your turn.

Ron

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Ronald P. Margraf Sr. who wrote (2387)2/28/2000 5:26:00 PM
From: JOHN F. MORGAN
   of 2395
 
Ron and Joe..
I have owned this one for a long time. Bought it because some broker was hyping it about in the 6 range. The selling point was the non invasive approach. What they have is big,
heavy, and not easily transportable as well as being very expensive.

Perspectives Weekend Edition - Feb 25
Date: Sun, 27 Feb 2000 11:46:05 -0700
From: Stock Perspectives <stockperspectives@home.com>

US Over the Counter Bulletin Board
==================================
Company Symbol Stockscore
Illinous Semi ISCO 87
DSL Net DSLN n/a
BioControl BICO 97 up from 77 previously
Verticale VCSY n/a
Antenna Amer. ANTM 98

This value appears to be just a measure of strength, but I like it about 8,000 shares worth.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: JOHN F. MORGAN who wrote (2388)2/28/2000 8:59:00 PM
From: Ronald P. Margraf Sr.
   of 2395
 
Hi John,

The T/As on BICO look good. The story is good. How good?, hard to say. But I think good enough to take this to 2 in the near term. Myself, I probably won't be around for the 2. Will probably take profits at 2xs and go. Move it back into ECNC for a much greater return. Looking for ECNC in the next few weeks to double or triple, after that, who knows.;-))))

As far a VCSY, how do you think I bought this one. Sold out of my position in VCSY and made a handsome profit last week. ;-))))

Now ANTM, NOW this is an interesting one. Almost bought this one today.;-))) Decided to wait. Been following this one and got it in the program. Like it but still looking for something that tells me that this is a winner. Missed the 1 move but then again, I don't look for the dollar but the double.;-)))) If I don't think I can make a double I don't get into it generally.;-( Sorry, but that is the only way to reduce my risk.

On that note, I'll bid you ado.

Catcha on the upside,

Ron

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Ronald P. Margraf Sr. who wrote (2389)2/28/2000 9:04:00 PM
From: Joe Lyddon
   of 2395
 
I wish you would NOT use 'fixed font'.

It makes it very difficult to read.

...but, I enjoyed what I read!

Thank you,
Joe

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Joe Lyddon who wrote (2390)2/28/2000 9:33:00 PM
From: Ronald P. Margraf Sr.
   of 2395
 
Hi Joe,

Didn't know. Just followed John's post. Guess it dose it automatically.

So what was so enjoyable?;-))))

Curious,

Ron

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10